Spotlight on Annals
The March issue of the Annals of Allergy, Asthma and Immunology, is full of exciting information that will satisfy the needs and desires of our readers for scientifically sound, clinically relevant information and features. I call your attention to two articles that should be of particular interest to many of you.
Each issue of the Annals of Allergy, Asthma and Immunology offers new opportunities for learning. The January issue is full of new features and manuscripts that will fulfil learning opportunities with wide and varying interests.
Two articles in particular are worth special mention. The first is the annual Year in Review: The Best of 2016 in the Annals, authored by the editors. We carefully selected these articles based upon our perception of greatest utility to our readers. It is a succinct way for you to see the highlights of the two volumes of the Annals published in 2016, organized based upon subheadings derived from the table of contents of each issue.
November is always a great learning month for College members as we get together for our Annual Scientific Meeting. This month’s issue of the Annals of Allergy, Asthma and Immunology is likewise full of great learning opportunities with reviews, original articles, letters and other features. In particular I would like to call your attention to two articles in the November Annals.
The upcoming October issue of the Annals of Allergy, Asthma and Immunology contains a large diversity of information in multiple formats including original articles, reviews, letters and others. Two articles in particular are worthy of mention.
The first is a retrospective study by Dr. Zazzali and colleagues that looked at three of the pivotal studies for the utility of omalizumab for chronic idiopathic urticaria in terms of the effects on accompanying episodes of angioedema. The study looked at results from all three pivotal trials (ASTER I, ASTER II, GLACIAL). Results indicated that higher dose omalizumab (300mg subcutaneously every four weeks) improved the percentage of angioedema free days compared to placebo. Interestingly, most of the episodes of angioedema in all groups was successfully managed with low intensity interventions – taking antihistamines or doing nothing.
As the practice of medicine continues to mature in the 21st century, more and more clinical conditions which have classically been categorized as single diseases are now better described as syndromes or, in modern terms, phenotypes. Phenotypes can be designated based upon a variety of factors including overt or subtle differences in clinical presentations, diagnostic criteria, comorbidity risk and/or selection of therapeutic approaches with differences in response. The September issue of the Annals of Allergy, Asthma and Immunology addresses this with two articles in particular that describe phenotypes of diseases we have encountered for some time but have not had great success in therapy.
The June issue of the Annals of Allergy, Asthma and Immunology, which will be online Tuesday, June 2, has many features for the practicing allergist-immunologist. Two interesting articles might seem to be a bit out of the “mainstream” offerings, but I recommend them because of their high potential to be of use in your practice in the near future.